Form 4: Tyra Biosciences Director Jake Simson Granted Stock Options

Director Jake Simson of Tyra Biosciences, Inc. was granted stock options for 18,600 shares on May 29, 2024, according to a Form 4 filing.

Summary

• Jake Simson, a director at Tyra Biosciences, Inc., was granted stock options to purchase 18,600 shares of common stock on May 29, 2024.
• The exercise price of the stock options is $15.94.
• The options vest monthly following the grant date, with any remaining unvested portion vesting on the date of the next annual meeting of the Issuer's stockholders, subject to continuous service.
• Simson holds the stock option for the benefit of RA Capital Healthcare Fund, L.P., the RA Capital Nexus Fund, L.P., and a separately managed account, and will turn over any net cash or stock received upon exercise to offset advisory fees.
• Simson disclaims beneficial ownership of the stock option and underlying Common Stock due to the arrangement with RA Capital Management, L.P.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding stock option grants, which is neither particularly positive nor negative. The sentiment is neutral.

Positives

• The grant of stock options to a director aligns their interests with the company's performance.

Future Outlook

The stock options vest monthly, with potential for full vesting at the next annual meeting, contingent on continuous service.

Industry Context

Stock option grants are a common form of compensation for directors in publicly traded companies, aligning their interests with shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotechnology industry, similar to companies like Amgen, Gilead Sciences, and Biogen.
• The vesting schedule of monthly vesting with potential for accelerated vesting at the annual meeting is also a common structure.

Key Dates